Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gao, B.
Right arrow Articles by Minna, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gao, B.
Right arrow Articles by Minna, J. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 275, Issue 16, 12237-12242, April 21, 2000


Functional Properties of a New Voltage-dependent Calcium Channel alpha 2delta Auxiliary Subunit Gene (CACNA2D2) *

Boning GaoDagger , Yoshitaka SekidoDagger , Anton Maximov§, Mohamad SaadDagger , Eva ForgacsDagger , Farida Latif, Ming H. Wei||, Michael Lerman||, Jung-Ha Lee**, Edward Perez-Reyes**, Ilya Bezprozvanny§, and John D. MinnaDagger Dagger Dagger

From the Dagger  Hamon Center for Therapeutic Oncology Research, Departments of Internal Medicine, Pharmacology, and § Physiology, University of Texas, Southwestern Medical Center, Dallas, Texas 75390,  University of Birmingham, Birmingham B15 2TT, United Kingdom, || Laboratory of Immunobiology, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland 21702, and ** Department of Pharmacology, University of Virginia, Charlottesville, Virginia 22908

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have positionally cloned and characterized a new calcium channel auxiliary subunit, alpha 2delta -2 (CACNA2D2), which shares 56% amino acid identity with the known alpha 2delta -1 subunit. The gene maps to the critical human tumor suppressor gene region in chromosome 3p21.3, showing very frequent allele loss and occasional homozygous deletions in lung, breast, and other cancers. The tissue distribution of alpha 2delta -2 expression is different from alpha 2delta -1, and alpha 2delta -2 mRNA is most abundantly expressed in lung and testis and well expressed in brain, heart, and pancreas. In contrast, alpha 2delta -1 is expressed predominantly in brain, heart, and skeletal muscle. When co-expressed (via cRNA injections) with alpha 1B and beta 3 subunits in Xenopus oocytes, alpha 2delta -2 increased peak size of the N-type Ca2+ currents 9-fold, and when co-expressed with alpha 1C or alpha 1G subunits in Xenopus oocytes increased peak size of L-type channels 2-fold and T-type channels 1.8-fold, respectively. Anti-peptide antibodies detect the expression of a 129-kDa alpha 2delta -2 polypeptide in some but not all lung tumor cells. We conclude that the alpha 2delta -2 gene encodes a functional auxiliary subunit of voltage-gated Ca2+ channels. Because of its chromosomal location and expression patterns, CACNA2D2 needs to be explored as a potential tumor suppressor gene linking Ca2+ signaling and lung, breast, and other cancer pathogenesis. The homologous location on mouse chromosome 9 is also the site of the mouse neurologic mutant ducky (du), and thus, CACNA2D2 is also a candidate gene for this inherited idiopathic generalized epilepsy syndrome.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Electrophysiological and molecular cloning studies have revealed an incredible diversity of voltage-gated calcium channels. They are formed by heteromultimeric complexes of alpha 1, alpha 2delta , beta , and gamma  subunits. The alpha 1 subunits contain the channel pore, voltage sensors, and the receptors for various classes of drugs and toxins (1). There are three families of alpha 1 subunits: the L-type, Cav1, family, composed of alpha 1S, alpha 1C (Cav1.2), alpha 1D, and alpha 1F; the non-L-type high voltage-activated, or Cav2, family, which contains the P/Q-types encoded by alpha 1A, the N-type encoded by alpha 1B (Cav2.2), and R-types encoded by alpha 1E; and the T-type family, or Cav3, encoded by alpha 1G (Cav3.1), alpha 1H, and alpha 1I (2). The beta  subunit family is less diverse, with only four genes cloned so far (3). Co-expression studies have established two physiological roles of beta  subunits in high voltage-activated Ca2+ channels: they dramatically increase alpha 1 expression at the plasma membrane, and they alter the biophysical properties of the channel currents. In general, beta  subunits have little effect on the expression of low voltage-activated currents (4). Although only one gamma  and alpha 2delta subunit have been characterized biochemically, recent evidence suggests that there may be additional members of these gene families (5-7). The gamma 1 subunit was shown to be part of the skeletal muscle L-type channel (8); coexpression studies have indicated that it aids in the formation of L-type channels, as assayed by dihydropyridine binding (9), and may play a role in channel inactivation (10).

The alpha 2delta subunit (alpha 2delta -1) was first identified in biochemical studies of skeletal muscle L-type Ca2+ channels (reviewed in Ref. 1). Using antibodies, it has also been shown to be part of the cardiac L-type and neuronal N-type channels (11, 12). alpha 2delta -1 cDNA has been cloned from skeletal muscle and brain cDNA libraries (13-15). The 175-kDa protein product is post-translationally cleaved to form disulfide-linked alpha 2 and delta  peptides, both of which are heavily glycosylated. Biochemical and mutation analysis supports a single transmembrane domain in the delta  subunit that anchors the alpha 2delta protein to the membrane (16). Coexpression of alpha 2delta -1 with both high voltage-activated and low voltage-activated alpha 1 subunits facilitates the assembly of channels in the plasma membrane (4, 9, 17). Coexpression studies also indicate that alpha 2delta -1 can alter the pharmacological properties of L-type channels (18). In contrast to the beta  subunits that have a dramatic effect on gating of all high voltage-activated channel in many expression systems, the effects of alpha 2delta -1 are more controversial, perhaps depending on the alpha 1 subunit used or the expression system. For example, alpha 2delta -1 has little or no effect on either L-type (18, 19) or N-type currents expressed in Xenopus oocytes (17) but appears to affect inactivation of L-type channels expressed in mammalian cells (20, 21). The opposite result occurred in studies on alpha 1E-mediated currents, where no effect was observed in mammalian cells (22) and effects on channel inactivation were observed in Xenopus oocytes (23). The alpha 2delta -1 subunit has a high affinity binding site for the anti-epileptic drug gabapentin (16). Gabapentin has been shown to modestly inhibit (~30%) neuronal Ca2+ currents, although it is unclear if this is its mechanism of action (24).

We have been attempting to identify a new human tumor suppressor gene in chromosome region 3p21.3, where frequent allele loss and occasional homozygous deletions have been found in lung, breast, and other human tumors (25). Several genes in the region have been identified using positional cloning strategies. The sequence of one of the genes and its mRNA splicing variants in the region (alpha 2delta -2; GenBankTM numbers AF040709, AF042792, and AF042793; CACNA2D2) showed extensive homology with the known calcium channel alpha 2delta -1 subunit. We have studied the tissue distribution of expression of this new alpha 2delta -2 gene and tested the function of the gene product in Xenopus oocytes by coexpressing alpha 2delta -2 cRNAs along with a representative member of the three families of calcium subunit alpha 1 subunits. We find a pattern of expression different from the other alpha 2delta subunit, whereas the alpha 2delta -2 enhances the activity of the calcium subunit alpha 1 subunits.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Positional Cloning of alpha 2delta -2 cDNA-- A contig1 of 22 cosmids covering 600 kb localized to the 3p21.3 small cell lung cancer homozygous deletions isolated from a human placental cosmid library have been described previously (25). The entire contig was sequenced by the joint effort of the Sanger Center (UK) and the Washington University Genome Sequence Center. The obtained sequence information was analyzed by BLAST and GENSCAN Informatics as well as the integrated informatic software package developed by the Garner lab at UT Southwestern, PANORAMA, and we found that cosmid LUCA#11 harbored an EST clone N53512 (Genome Systems) containing a portion of the 3' end as well as putative exons of what would be alpha 2delta -2. Further Southern blot analysis showed that various exons of the alpha 2delta -2 gene are located on cosmid LUCA06 (GenBankTM number Z84493), LUCA07 (GenBankTM number Z84494), LUCA08 (GenBankTM number Z84495), LUCA09 (GenBankTM number Z75743) LUCA10 (GenBankTM number Z75742), and LUCA11 (GenBankTM number Z84492). Based on GENSCAN predictions, a primer set of LUCA11pr5, 5'-CTGAGAGTGAGGATGTGGAA-3'(sense primer), and LUCA11pr18, 5'-GTGCATCCTCATACACGTTG-3' (antisense primer), was used for reverse transcriptase-polymerase chain reaction amplification for normal lung cDNA template, and a 960-base pair product was successfully amplified. The 1.5-kb NotI/HindIII fragment of the EST clone N53512 and the 960-base pair product were used as probes on human multiple tissue Northern blots (CLONTECH). The screening of a million clones from a lung cDNA library (CLONTECH) with the 960-base pair reverse transcriptase-polymerase chain reaction product yielded 120 positive clones, which were also screened by probing clone N53512 to obtain the clones with long inserts. Five clones randomly selected as single positives for the 960-base pair probe and 5 clones selected as double positive for both probes were subcloned and sequenced. All of the 10 clones had the sequence of alpha 2delta -2, suggesting that all of the 120 clones were alpha 2delta -2. Two clones (pY720c21 and pY724c95) that covered the longest sequence were assembled and further inserted into a plasmid expression vector pcDNA3.1 (Invitrogen) by standard methods.

Northern Blot Analysis-- Human multiple tissue Northern blots (CLONTECH) were hybridized and washed according to the manufacturer's recommendation. The three short probes were generated using polymerase chain reaction. All probes were labeled with a random-oligonucleotide priming kit (Rad Prime DNA labeling System, Life Technologies, Inc.).

In Vitro Translation and Transient Transfection Studies-- alpha 2delta -2 cDNA inserted into plasmid pcDNA3.1 (Invitrogen) was used for in vitro translation using [35S]methionine in an in vitro transcription/translation system (TNT Coupled Reticulocyte Systems, Promega). For transfection experiments, non-small cell lung cancer NCI-H1299 cells (3 × 105) were seeded in 3.5-cm culture dishes for 24 h in RPMI 1640 containing 5% fetal bovine serum, and then 1 µg of cloned DNA was introduced into the cells using the LipofectAMINE reagent (Life Technologies, Inc.). For protein expression after transfection, cells were harvested 48 h later and were lysed in 80 µl of sample buffer (50 mM Tris, pH 6.8, 1% SDS, 10% glycerol, and 0.3M of beta -mercaptoethanol). NCI-H1299 cells were used for these studies because they do not express endogenous alpha 2delta -2 mRNA or protein (see "Results") and are homozygous for multiple polymorphic markers in the 600-kb homozygous deletion region (26) and, thus, have undergone loss of heterozygosity for this region.

Antibodies and Western Blots-- Peptide A (YYDAKADAELDDPESEDVERG), corresponding to amino acids 161-181 of alpha 2delta -2 (GenBankTM number AF040709), was synthesized, and rabbit polyclonal antibodies were raised using a commercial source (Alpha Diagnostic, San Antonio, TX). Antibodies were affinity-purified using this peptide conjugated to agarose beads (amino link immobilization kit; Pierce). Horseradish peroxidase-labeled anti-rabbit antibody and chemiluminescent substrates were used to detect the positive signal.

Electrophysiologic Studies-- For the study of coexpression with alpha 1B and beta 3 subunits, complementary RNA (cRNA) encoding human brain alpha 1B (27), rabbit skeletal muscle alpha 2delta -1(28), rabbit beta 3 (29), and alpha 2delta -2 subunits was synthesized in vitro using T7 RNA polymerase, resuspended in water at a final concentration of ~1 mg/ml, and stored at -80 °C until injection. Xenopus oocytes harvested by standard methods (30) were injected with a mixtures of the following transcripts: alpha 1B+beta 3, alpha 1B+beta 3+alpha 2delta -1, alpha 1B+beta 3+alpha 2delta -2, or alpha 2delta -2 alone (approximately 50 ng of total cRNA/oocyte). Two days later oocytes were analyzed using standard two-electrode voltage-clamp technique with 5 mM Ba2+ as a charge carrier (31). The holding potential was -120 mV. Currents were recorded in response to test potentials ranging from -110 to +100 mV, filtered at 200 Hz, then analyzed using pClamp 6.04 (Axon Instruments) and Origin (Microcal) software. Leak and capacitance currents were subtracted on-line with a P/4 protocol.

For the studies of coexpression with alpha 1C and alpha 1G subunits, cRNA of either alpha 1C, alpha 1G, or alpha 2delta -2 cDNA was synthesized using Ambion Megascript kit according to the supplier's protocol (Ambion, Austin, TX). Due to low expression of wild-type alpha 1C, we used the modified cDNA Delta N60, which is truncated by 60 amino acids at the N-terminal end of the rabbit cardiac alpha 1 subunit (32). The rat brain alpha 1G cDNA (33) was contained in the vector pGEM-HE (34). Fifty nl of cRNA (5 ng for alpha 1C, 5 ng for alpha 1G, and 2.5 ng for alpha 2delta -2) of either alpha 1C alone, alpha 1C plus alpha 2delta -2, alpha 1G alone, or alpha 1G plus alpha 2delta -2 were injected into each oocyte using a Drummond Nanoject pipette injector (Parkway, PA). Expression of injected cRNA was measured from the 4th day after injection for alpha 1C alone or alpha 1C plus alpha 2delta -2 and the 6-7th day after injection for alpha 1G alone or alpha 1G plus alpha 2delta -2 using the two-electrode voltage clamp method. Currents were measured in either 40 mM Ba2+ solution (40 mM Ba(OH)2, 50 mM NaOH, 1 mM KOH, and 5 mM HEPES, adjusted to pH 7.4 with methanesulfonic acid) for L-type currents or 10 mM Ba2+ solution (10 mM Ba(OH)2, 80 mM NaOH, 1 mM KOH, and 5 mM HEPES, adjusted to pH 7.4 with methanesulfonic acid) for T-type currents. Data were sampled at either 2 kHz for L-type currents or 5 kHz for T-type currents using the pClamp 6 system via a Digidata 1200 A/D converter (Axon Instrument, Foster city, CA). Leak currents were subtracted using a P/+4 for L-type currents or a P/-6 for T-type currents.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Characteristics of alpha 2delta -2 cDNA and Its Predicted Amino Acid Sequence-- Human chromosome 3p21.3 is deleted in many small cell lung cancers. While searching for a putative tumor suppressor gene in this region, we identified a gene (GenBankTM number AF040709, AF042792, and AF042793) that appeared to encode a homolog of the alpha 2delta subunit of Ca2+ channels. An open reading frame of 3,435 nucleotides encoding 1,145 amino acids was identified. The molecular mass of the deduced amino acid sequence is 129,343 Da. BLAST searches and homology alignment revealed that the predicted protein shares 56% amino acid sequence identity with the human auxiliary alpha 2delta -1 subunit (GenBankTM number M76559) of voltage-gated Ca2+ channels (13). Therefore we refer to the gene product as alpha 2delta -2 and the gene as CACNA2D2. Notably, 17 out of 22 cysteines in alpha 2delta -2 are conserved with alpha 2delta -1, suggesting that the two proteins share similar overall secondary structure. Similar to the alpha 2delta -1 subunit, the alpha 2delta -2 sequence contains multiple putative N'-glycosylation sites and is likely to be glycosylated.

Tissue Specificity of alpha 2delta -2 Expression-- Tissue distribution of alpha 2delta -2 expression was examined by Northern blot hybridization of the human multiple tissue blots (CLONTECH) using the entire coding region (Fig. 1, A and B) as well as three different short probes (nucleotides 510-653 (Fig. 1C) and nucleotides 993-1152 (Fig. 1D) and 2729-3293 (Fig. 1E). An approximately 5.5-kb alpha 2delta -2 mRNA was found and appeared most abundant in lung and testis, abundant in brain, heart, and pancreas, and detected at low amounts in prostate and skeletal muscle in all of the four Northern blot analysis. The significance of the results will be discussed in the discussion section.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 1.   Expression of alpha 2delta -2 in normal human tissues. Human multiple tissue blots (CLONTECH) were hybridized with 32P-labeled cDNA synthesized from the entire coding sequence of alpha 2delta -2 (A and B). Sizes of the RNA markers are indicated on the left. PBL, peripheral blood lymphocyte. Probes for C, D, and E are indicated at the bottom of each figure.

Biochemical Properties of the alpha 2delta -2 Protein-- To characterize the biochemical properties of alpha 2delta -2 protein, we translated the alpha 2delta -2 cDNA in vitro and in vivo. The product of in vitro translation is a single band with the molecular mass of ~130 kDa (Fig. 2A), which is consistent with the calculated molecular mass of 129,268 Daltons. For in vivo expression, the alpha 2delta -2 coding sequence was inserted into the mammalian expression vector pcDNA3.1 (Invitrogen) and transfected into non-small cell lung cancer cell line NCI-H1299, which does not express alpha 2delta -2 mRNA or its protein (Fig. 2C). An affinity-purified anti-alpha 2delta -2 peptide antibody detected an ~150-kDa protein in the lysate from alpha 2delta -2-transfected cells but not in cells transfected with the vector control (Fig. 2B). Most likely, the increase in the apparent molecular mass (129 to 150 kDa) compared with the conceptually translated protein is the result of N'-glycosylation, in agreement with multiple putative N-glycosylation sites in the alpha 2delta -2 sequence, which represent known properties of the alpha 2delta -1 protein (35). Endogenous alpha 2delta -2 protein of 150 kDa was also detected in some lung tumor cell lines using the same antibody (Fig. 2C), which further confirmed our conceptual translation and anti-peptide antibody preparation were correct.


View larger version (67K):
[in this window]
[in a new window]
 
Fig. 2.   A, in vitro transcription and translation of alpha 2delta -2. Lane 1, in vitro transcription and translation of alpha 2delta -2 in expression vector pcDNA3.1. Lane 2, no DNA was added in the same reaction. The arrow indicates the expected 130 kDa product. B, Western blot analysis of transfection of NCI-H1299 cells with alpha 2delta -2. Lane 1, transfection of NCI-H1299 cells with alpha 2delta -2 in expression vector pcDNA3.1. Lane 2, transfection of NCI-H1299 cells with pcDNA3.1 vector alone. Affinity-purified anti-alpha 2delta -2 peptide antibody was used to detect the protein product. The arrow indicates the expected protein product. Sizes of the prestained protein molecular weight markers are indicated on the right. C, 40 µg of protein from tumor cell lysates were loaded in each lane. Lane 1, NCI-H2O77 (adenocarcinoma); lane 2, NCI-H358 (adenocarcinoma); lane 3, NCI-H2106 (large cell neuroendocrine carcinoma); lane 4, NCI-H1299 (large cell carcinoma) cells.

Functional Properties of alpha 2delta -2-- To test for functional expression of the alpha 2delta -2 subunit, we performed a series of two-electrode voltage clamp experiments using the Xenopus oocyte heterologous expression system. Injection of oocytes with cRNA encoding the pore-forming human alpha 1B subunit together with an auxiliary beta 3 subunit resulted in expression of functional N-type calcium channels in oocyte plasma membranes with a peak current of 1.0 ± 0.1 µA (n = 4) (Fig. 3A). Channel activity was indicated as representative inward barium currents observed in response to 0 mV and +20 mV test potentials. The magnitude of N-type currents was increased 9-fold to 9.1 ± 1.4 µA (n = 10) when alpha 1B and beta 3 were coexpressed with the rabbit skeletal muscle alpha 2delta -1 subunit (Fig. 3B). When co-expressed with alpha 1B and beta 3 subunits, the alpha 2delta -2 subunit exerted a similar effect on N-type channel expression, increasing peak current size to 7.6 ± 0.6 µA (n = 10) (Fig. 3C). No channel activity was observed after injection of alpha 2delta -2 cRNA alone (data not shown). By varying the test potential in the range from -100 mV to + 100 mV we established that the shape and position of current-voltage relationships was similar for all three subunit combinations, with the maximum current at 0 mV test potential and reversal potential at + 50 mV (Fig. 3D).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3.   Representative records of barium currents evoked by step depolarization from -120 to 0 mV and +20 mV. Oocytes were injected with cRNA encoding: A, alpha 1B+beta 3; B, alpha 1B+beta 3+alpha 2delta -1; C, alpha 1B+beta 3+alpha 2delta -2. Residual capacitance transients at the end of test pulses were removed. D, mean current-voltage curves from two independent injections (mean ± S.E.) with alpha 1B+beta 3 (open circles), alpha 1B+beta 3+alpha 2delta -1 (filled triangles), and alpha 1B+beta 3+alpha 2delta -2 (filled circles) cRNA combinations. E, current-voltage relationships of alpha 1C alone (filled circles) and alpha 1C/alpha 2delta -2 (circles) induced currents. Currents were evoked by a series of test pulses of -50 mV to +70 mV from a holding potential of -70 mV in 40 mM Ba2+ solution. Average alpha 1C currents were collected from 33 oocytes; alpha 1C/alpha 2delta -2 currents were from 31 oocytes isolated from three different frogs. Data represent the mean ± S.E. F, current-voltage relationships of alpha 1G (filled squares)- and alpha 1G/alpha 2delta -2 (squares)-induced currents. Currents were elicited by test pulses of -70 mV to +50 mV from a holding potential of -90 mV in 10 mM Ba2+ solution. Average alpha 1G currents were collected from 33 oocytes; alpha 1G/alpha 2delta -2 currents were from 32 oocytes isolated from four frogs. G, average stimulation of alpha 1C and alpha 1G currents by coexpression with alpha 2delta -2. Since expression of the cloned T-type channels is highly variable between batches of oocytes, each batch was injected with both alpha 1 and alpha 1alpha 2delta -2 and stimulation by alpha 2delta -2 was measured for each batch then averaged.

Stimulation of N-type current expression by alpha 2delta -1 and alpha 2delta -2 subunits (Fig. 3, A-C) is similar to the previously described effect of alpha 2delta -1 on P/Q-type Ca2+ channels formed by alpha 1A and beta  subunits (36, 37), which has been shown to depend on alpha 2delta -1 subunit glycosylation (35). Thus, it is likely that alpha 2delta -2 subunit is glycosylated when expressed in Xenopus oocytes, as is expected from biochemical and sequence analysis. Noticeably, the alpha 2delta -1 but not the alpha 2delta -2 subunit was able to hasten N-type Ca2+ channel inactivation. Indeed, at the end of a 50-ms test pulse to +20 mV, the size of the current was reduced to 33 ± 10% (n = 8) of the peak current for alpha 1B+beta 3+alpha 2delta -1, to 59 ± 5% (n = 24) of the peak current for alpha 1B+beta 3+alpha 2delta -2, and to 51 ± 4% (n = 15) of the peak current for alpha 1B+beta 3 subunit combinations.

To test for an alpha 2delta -2 effect on L-type channels, either alpha 1C cRNA alone or alpha 1C plus alpha 2delta -2 cRNA were injected into oocytes. Peak currents measured during a series of test potentials were averaged (Fig. 3E). When peak current amplitudes measured at +30 mV were compared, alpha 1C/alpha 2delta -2 currents were significantly larger than alpha 1C by 201% (t test, p < 0.001). However, there were no significant differences in the position of the current-voltage curves, which peaked at ~+35 mV. Similar to the alpha 2delta -2 effect on alpha 1C channels, coinjection of alpha 2delta -2 cRNA with alpha 1G cRNA increased T-type current amplitudes by 176% (t test, p < 0.05), compared with alpha 1G alone (Fig. 3F). There were no significant differences in their biophysical properties including activation threshold, position of their current-voltage curves, reversal potentials, and activation and inactivation kinetics. We conclude from these experiments that the cloned alpha 2delta -2 protein is able to function as an auxiliary subunit of all three subfamilies of voltage-gated Ca2+ channels.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

This study describes the cloning and functional properties of a novel alpha 2delta subunit of voltage-gated Ca2+ channels. The gene (CACNA2D2) was discovered by positional cloning while searching for a lung cancer tumor suppressor gene. GenBankTM deposits AF040709 and AF042792 represent alternatively spliced forms (in the 5'-untranslated region) with the same conceptual 1,145-amino acid sequence. GenBankTM deposit AF042793 represents another 5' alternatively spliced form uncommonly found in lung cDNA clones resulting in an open reading frame beginning at the second 5' methionine at codon 70 and, thus, resulting in a deletion of the 70 N-terminal amino acids found in the common alpha 2delta -2 form studied here. Sequences were deposited in the GenBankTM to stimulate research on its function. Klugbauer et al. (7) cloned another related alpha 2delta subunit, then proposed the following nomenclature: alpha 2delta -1, for the original alpha 2delta cloned from skeletal muscle; alpha 2delta -2, for the protein described herein, and alpha 2delta -3, for their novel sequence. Similarly the genes will be referred to as CACNA2D1, CACNA2D2, and CACNA2D3, respectively (38). While this paper was in preparation, an alpha 2delta -2 clone (KIAA0558, GenBankTM number AB011130) was independently isolated by the Kazusa DNA Research Institute from human brain as part of large scale anonymous cDNA sequencing efforts (39). The present study reports on the expression of the CACNA2D2 gene in human tissues and on electrophysiological studies that show it can modulate the expression of functional Ca2+ channels.

Expression of the CACNA2D2 gene was determined by Northern analysis. It was most highly expressed in lung and testis, well expressed in brain, heart, and pancreas, and expressed to a lower extent in skeletal muscle and prostate. Our results do not agree with those of Klugbauer et al. (7), who found abundant cross-reactive material from what they reported to be alpha 2delta -2 in mRNA from skeletal muscle, pancreas, and heart, with hardly any signal from lung. We feel our expression pattern is the correct one since we had performed four independent Northern blot analysis using four probes including one (nt 2729-3293) that is very similar to the probe that Klugbauer et al. (7) used (nucleotides 2877-3249).The result of our cDNA screening also supports the high expression of alpha 2delta -2 in lung, since we obtained 120 alpha 2delta -2 clones from a screening of 1 million clones of a lung cDNA library. A possible explanation for the discrepancy could be that their probe cross-reacted with alpha 2delta -1, since it has an expression pattern very similar to what they reported for alpha 2delta -2 (40). Furthermore, it is unlikely that alpha 2delta -2 is highly expressed in skeletal muscle, because alpha 2delta proteins were purified from that tissue, and only the sequence of alpha 2delta -1 was detected (13).

The tissue distribution of mRNA for the three alpha 2delta subunits is very different (7, 40). All three genes are expressed in brain, which is the only tissue that expresses alpha 2delta -3. The alpha 2delta -1 gene is highly expressed in skeletal muscle, where we find little or no expression of alpha 2delta -2. Both alpha 2delta -1 and -2 are expressed in heart. The alpha 2delta -2 gene is highly expressed in lung where the expression of alpha 2delta -1 is low. It will be important to determine what cells in the lung express alpha 2delta -2; however, we have shown that several lung cancers representing different lung epithelial types can express alpha 2delta -2, so that presumably some normal lung epithelial cells also express alpha 2delta -2. In this regard, it is also interesting to note that alpha 1C was cloned from lung cDNA libraries (19), and L-type currents have been characterized from tracheal smooth muscle (41). The only beta  subunit detected in lung mRNA is beta 2 (3). Therefore, the minimum subunit composition of lung L-type channels can be deduced as alpha 1Calpha 2delta -2beta 2.

The possible role of alpha 2delta -2 as a Ca2+ channel subunit was examined using the Xenopus oocyte expression system. We tested for an effect on currents using three alpha 1 subunits. The alpha 1 subunits were chosen to represent each of the three subfamilies of Ca2+ channels: Cav1.2 or alpha 1C, Cav2.2 or alpha 1B, and a low voltage-activated channel Cav3.1 or alpha 1G. In each case, alpha 2delta -2 was able to stimulate functional expression. No effect was observed on the biophysical properties of the current, suggesting that alpha 2delta -2 simply increased the number of functional channels at the plasma membrane. Similar results were obtained with alpha 2delta -1 on the expression of alpha 1G in both COS cells and Xenopus oocytes (4).

Coexpression studies of alpha 2delta -2 plus alpha 1B also included the beta 3 subunit. In these experiments we observed the largest stimulatory effect on expression. Some studies report a synergistic action of alpha 2 and beta  on alpha 1B expression (17). The experiments with alpha 1C did not include a beta  subunit because they stimulate current so much already that it has been difficult to see any effect of alpha 2delta at the whole cell level (18).

Interest in the physiological roles of Ca2+ channels has increased due to findings that mutations in their genes can lead to human diseases (42). In addition, defects in the auxiliary subunits of Ca2+ channels have been described in mouse models of absence epilepsy. These include mouse strains that have lost the expression of beta 4 and the recently discovered gamma 2 subunit (5, 43). In this regard, after we cloned CACNA2D2 we noted with great interest that the syntenic region in the mouse (mouse chromosome 9, 59.0-60.0 centimorgan) contains the mouse mutant ducky and also 4 other flanking genes (CISH, GNAI2, GNAT, and HYAL1) that we have identified in our ~600-kb region (25) and deposited as GenBankTM numbers AF132297 for CISH and U03056 for HYAL1. Our partial mouse cDNA sequence is 92% identical to the human alpha 2delta -2 sequence (GenBankTM number AF169633.1). In fact, preliminary evidence suggests that loss of alpha 2delta -2 expression leads to the epileptic phenotype, ducky (44). Histological examination of mouse ducky mutants reveals atrophy of the cerebellum, medulla oblongata, and spinal cord (45). These mice develop a spike-and-wave phenotype in the electroencephalogram, which is similar to that observed in absence epilepsy patients. Thus, it will be of great interest to see if inherited defects in CACNA2D2 also occur in humans (46). It remains to be determined how these Ca2+ channel defects lead to these epileptic phenotypes.

We began these studies searching for a human lung cancer tumor suppressor gene. The specific 600-kb 3p21.3 chromosome region within which the CACNA2D2 gene resides is a site of homozygous deletions occurring in lung and breast cancer and is a frequent target region for allele loss occurring very early in the pathogenesis of lung and other cancers (25, 47-49). Thus, we are also studying CACNA2D2 for mutations, expression alterations, and functional characteristics of a tumor suppressor gene in these cancers. In this regard we were interested to see its high expression in normal lung tissue and in some but not all lung cancer cell lines. A clinical connection between voltage-dependent calcium channels and lung cancer is well established by the Lambert-Eaton myasthenic syndrome, seen in some small cell lung cancer patients (50). Lambert-Eaton myasthenic syndrome is a human autoimmune disorder that impairs neuromuscular transmission such that patients with this syndrome have a defect in the Ca2+-dependent quantal release of acetylcholine from motor nerve terminals (51). In this syndrome patients develop antibodies (presumably initiated by expression of the channel proteins in their small cell lung cancer) that react with voltage-gated calcium channel polypeptides that block depolarization-induced Ca2+ influx, leading to the myasthenia (52-54). In this report we have seen alpha 2delta -2 to functionally interact with the T-type channel subunit alpha 1G. Thus, it was of great interest to us when Toyota et al. (55) reported that CACNA1G encoding this subunit could have its expression inactivated by aberrant methylation of its 5' CpG island in human tumors such as colorectal cancers, gastric cancers, and acute myelogenous leukemias. CACNA1G maps to chromosome region 17q21, another site of frequent allele loss in human cancer. Such acquired CpG island methylation in promoter regions of cancer cells as an acquired abnormality silencing genes such as tumor suppressor genes is well described (56, 57). Ca2+ influx via voltage-gated calcium channels including T-type channels and intracellular calcium signaling plays a role in apoptosis (58). In addition, platelet-derived growth factor-stimulated calcium influx changed during transformation of mouse C3H 10T1/2 fibroblasts accompanied by a marked reduction in expression of T-type calcium channels (59). Thus, the inactivation of voltage-gated calcium channel subunits such as CACNA2D2 and CACNA1G by any of several means merit serious consideration as an important step in cancer pathogenesis.

    ACKNOWLEDGEMENTS

We thank Meena Viswanathan, Yang Song, and David Burbee for assistance in this research.

    FOOTNOTES

* This work was supported by National Institutes of Health (NCI) Grants CA71618, P50-CA70907, NS38691, and NO1-CO-56000 and by the Hibino Memorial Medical Fund.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Dagger To whom correspondence should be addressed: Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8593. Tel.: 214-648-4900; Fax: 214-648-4940; E-mail: minna@simmons.swmed.edu.

    ABBREVIATIONS

The abbreviations used are: contig, group of overlapping clones; kb, kilobase(s).

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Perez-Reyes, E., and Schneider, T. (1995) Kidney Int. 48, 1111-1124[Medline] [Order article via Infotrieve]
2. Randall, A., and Benham, C. (1999) Mol. Cell. Neurosci. 14, 255-272[CrossRef][Medline] [Order article via Infotrieve]
3. Castellano, A., and Perez-Reyes, E. (1994) Biochem. Soc. Trans. 22, 483-488[Medline] [Order article via Infotrieve]
4. Dolphin, A. C., Wyatt, C. N., Richards, J., Beattie, R. E., Craig, P., Lee, J.-H., Cribbs, L. L., Volsen, S. G., and Perez-Reyes, E. (1999) J. Physiol. (Lond) 519, 35-45[Abstract/Free Full Text]
5. Letts, V. A., Felix, R., Biddlecome, G. H., Arikkath, J., Mahaffey, C. L., Valenzuela, A., Bartlett II, F. S., Mori, Y., Campbell, K. P., and Frankel, W. N. (1998) Nat. Genet. 19, 340-347[CrossRef][Medline] [Order article via Infotrieve]
6. Black, J. L., III, and Lennon, V. A. (1999) Mayo Clin. Proc. 74, 357-61[Abstract]
7. Klugbauer, N., Lacinova, L., Marais, E., Hobom, M., and Hofmann, F. (1999) J. Neurosci. 19, 684-691[Abstract/Free Full Text]
8. Sharp, A. H., and Campbell, K. P. (1989) J. Biol. Chem. 264, 2816-2825[Abstract/Free Full Text]
9. Suh-Kim, H., Wei, X., Klos, A., Pan, S., Ruth, P., Flockerzi, V., Hofmann, F., Perez-Reyes, E., and Birnbaumer, L. (1996) Receptors & Channels 4, 217-225[Medline] [Order article via Infotrieve]
10. Singer, D., Biel, M., Lotan, I., Flockerzi, V., Hofmann, F., and Dascal, N. (1991) Science 253, 1553-1557[Abstract/Free Full Text]
11. Schmid, A., Barhanin, J., Coppola, T., Borsotto, M., and Lazdunski, M. (1986) Biochemistry 25, 3492-3495[CrossRef][Medline] [Order article via Infotrieve]
12. McEnery, M. W., Snowman, A. M., Sharp, A. H., Adams, M. E., and Snyder, S. H. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 11095-11099[Abstract/Free Full Text]
13. Ellis, S. B., Williams, M. E., Ways, N. R., Brenner, R., Sharp, A. H., Leung, A. T., Campbell, K. P., McKenna, E., Koch, W. J., Hui, A., et al.. (1988) Science 241, 1661-1664[Abstract/Free Full Text]
14. De Jongh, K. S., Warner, C., and Catterall, W. A. (1990) J. Biol. Chem. 265, 14738-14741[Abstract/Free Full Text]
15. Williams, M. E., Feldman, D. H., McCue, A. F., Brenner, R., Velicelebi, G., Ellis, S. B., and Harpold, M. M. (1992) Neuron 8, 71-84[CrossRef][Medline] [Order article via Infotrieve]
16. Brown, J. P., and Gee, N. S. (1998) J. Biol. Chem. 273, 25458-25465[Abstract/Free Full Text]
17. Brust, P. F., Simerson, S., Mccue, A. F., Deal, C. R., Schoonmaker, S., Williams, M. E., Velicelebi, G., Johnson, E. C., Harpold, M. M., and Ellis, S. B. (1993) Neuropharmacology 32, 1089-1102[CrossRef][Medline] [Order article via Infotrieve]
18. Wei, X., Pan, S., Lang, W., Kim, H., Schneider, T., Perez-Reyes, E., and Birnbaumer, L. (1995) J. Biol. Chem. 270, 27106-27111[Abstract/Free Full Text]
19. Biel, M., Ruth, P., Bosse, E., Hullin, R., Stuhmer, W., Flockerzi, V., and Hofmann, F. (1990) FEBS Lett. 269, 409-412[CrossRef][Medline] [Order article via Infotrieve]
20. Shirokov, R., Ferreira, G., Yi, J., and Rios, E. (1998) J. Gen. Physiol. 111, 807-823[Abstract/Free Full Text]
21. Bangalore, R., Mehrke, G., Gingrich, K., Hofmann, F., and Kass, R. S. (1996) Am. J. Physiol. 270, H1521-H1528[Abstract/Free Full Text]
22. Jones, L. P., Wei, S. K., and Yue, D. T. (1998) J. Gen. Physiol. 112, 125-143[Abstract/Free Full Text]
23. Qin, N., Olcese, R., Stefani, E., and Birnbaumer, L. (1998) Am. J. Physiol. 274, C1324-C1331[Abstract/Free Full Text]
24. Stefani, A., Spadoni, F., and Bernardi, G. (1998) Neuropharmacology 37, 83-91[CrossRef][Medline] [Order article via Infotrieve]
25. Wei, M. H., Latif, F., Bader, S., Kashuba, V., Chen, J. Y., Duh, F. M., Sekido, Y., Lee, C. C., Geil, L., Kuzmin, I., Zabarovsky, E., Klein, G., Zbar, B., Minna, J. D., and Lerman, M. I. (1996) Cancer Res. 56, 1487-1492[Abstract/Free Full Text]
26. Fondon, J. W., III, Mele, G. M., Brezinschek, R. I., Cummings, D., Pande, A., Wren, J., O'Brien, K. M., Kupfer, K. C., Wei, M. H., Lerman, M., Minna, J. D., and Garner, H. R. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7514-7519[Abstract/Free Full Text]
27. Ellinor, P. T., Zhang, J. F., Horne, W. A., and Tsien, R. W. (1994) Nature 372, 272-275[CrossRef][Medline] [Order article via Infotrieve]
28. Tanabe, T., Takeshima, H., Mikami, A., Flockerzi, V., Takahashi, H., Kangawa, K., Kojima, M., Matsuo, H., Hirose, T., and Numa, S. (1987) Nature 328, 313-318[CrossRef][Medline] [Order article via Infotrieve]
29. Hullin, R., Singer-Lahat, D., Freichel, M., Biel, M., Dascal, N., Hofmann, F., and Flockerzi, V. (1992) EMBO J. 11, 885-890[Medline] [Order article via Infotrieve]
30. Rudy, B., and Iverson, L. E. (1992) in Methods in Enzymology (Abelson, J. N. , and Simon, M. I., eds), Vol. 207 , pp. 225-390, Academic Press, Inc., San Diego
31. Bezprozvanny, I., Scheller, R. H., and Tsien, R. W. (1995) Nature 378, 623-626[CrossRef][Medline] [Order article via Infotrieve]
32. Wei, X., Neely, A., Olcese, R., Lang, W., Stefani, E., and Birnbaumer, L. (1996) Receptors & Channels 4, 205-215[Medline] [Order article via Infotrieve]
33. Perez-Reyes, E., Cribbs, L. L., Daud, A., Lacerda, A. E., Barclay, J., Williamson, M. P., Fox, M., Rees, M., and Lee, J.-H. (1998) Nature 391, 896-900[CrossRef][Medline] [Order article via Infotrieve]
34. Chuang, R. S.-I., Jaffe, H., Cribbs, L. L., Perez-Reyes, E., and Swartz, K. J. (1998) Nat. Neurosci. 1, 668-674[CrossRef][Medline] [Order article via Infotrieve]
35. Gurnett, C. A., De Waard, M., and Campbell, K. P. (1996) Neuron 16, 431-440[CrossRef][Medline] [Order article via Infotrieve]
36. De Waard, M., and Campbell, K. P. (1995) J. Physiol. (Lond.) 485, 619-634[Abstract/Free Full Text]
37. Walker, D., and De Waard, M. (1998) Trends Neurosci. 21, 148-154[CrossRef][Medline] [Order article via Infotrieve]
38. Lory, P., Ophoff, R. A., and Nahmias, J. (1997) Hum. Genet. 100, 149-150[CrossRef][Medline] [Order article via Infotrieve]
39. Nagase, T., Ishikawa, K., Miyajima, N., Tanaka, A., Kotani, H., Nomura, N., and Ohara, O. (1998) DNA Res. 5, 31-39[Abstract]
40. Angelotti, T., and Hofmann, F. (1996) FEBS Lett. 397, 331-337[CrossRef][Medline] [Order article via Infotrieve]
41. Welling, A., Felbel, J., Peper, K., and Hofmann, F. (1992) Am. J. Physiol. 262, L351-L359[Abstract/Free Full Text]
42. Lehmann-Horn, F., and Jurkat-Rott, K. (1999) Physiol. Rev. 79, 1317-1372[Abstract/Free Full Text]
43. Burgess, D. L., Jones, J. M., Meisler, M. H., and Noebels, J. L. (1997) Cell 88, 385-392[CrossRef][Medline] [Order article via Infotrieve]
44. Barclay, J., Kusumi, K., Lander, E., Perez-Reyes, E., Frankel, W., Gardiner, M., and Rees, M. (1999) Epilepsia 40, 137
45. Meier, H. (1968) Acta Neuropathol. 11, 15-28[CrossRef][Medline] [Order article via Infotrieve]
46. Noebels, J. L. (1994) in Idiopathic Generalized Epilepsies: Clinical, Experimental, and Genetic Aspects (Malafosse, A. , Genton, P. , Hirsch, E. , Marescaux, D. , Broglin, D. , and Bernasconi, R., eds) , pp. 215-225, John Libbey & Co. Ltd., London
47. Sekido, Y., Ahmadian, M., Wistuba, II, Latif, F., Bader, S., Wei, M. H., Duh, F. M., Gazdar, A. F., Lerman, M. I., and Minna, J. D. (1998) Oncogene 16, 3151-3157[CrossRef][Medline] [Order article via Infotrieve]
48. Sekido, Y., Fong, K., and Minna, J. (1998) Biochim. Biophys. Acta 1378, F21-F59[Medline] [Order article via Infotrieve]
49. Wistuba, I., Behrens, C., Milchgrub, S., Bryant, D., Hung, J., Minna, J. D., and Gazdar, A. F. (1999) Oncogene 18, 643-650[CrossRef][Medline] [Order article via Infotrieve]
50. Takamori, M. (1999) Intern. Med. 38, 86-96[Medline] [Order article via Infotrieve]
51. O'Neill, J. H., Murray, N. M., and Newsom-Davis, J. (1988) Brain 111, 577-596[Abstract/Free Full Text]
52. Lennon, V. A., Kryzer, T. J., Griesmann, G. E., O'Suilleabhain, P. E., Windebank, A. J., Woppmann, A., Miljanich, G. P., and Lambert, E. H. (1995) N. Engl. J. Med. 332, 1467-1474[Abstract/Free Full Text]
53. Raymond, C., Walker, D., Bichet, D., Iborra, C., Martin-Moutot, N., Seagar, M., and De Waard, M. (1999) Neuroscience 90, 269-277[CrossRef][Medline] [Order article via Infotrieve]
54. Voltz, R., Carpentier, A. F., Rosenfeld, M. R., Posner, J. B., and Dalmau, J. (1999) Muscle Nerve 22, 119-122[CrossRef][Medline] [Order article via Infotrieve]
55. Toyota, M., Ho, C., Ohe-Toyota, M., Baylin, S. B., and Issa, J. P. (1999) Cancer Res. 59, 4535-4541[Abstract/Free Full Text]
56. Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., and Issa, J. P. (1998) Adv. Cancer Res. 72, 141-196[Medline] [Order article via Infotrieve]
57. Schmutte, C., and Jones, P. A. (1998) Biol. Chem. Hoppe-Seyler 379, 377-88
58. Berridge, M. J., Bootman, M. D., and Lipp, P. (1998) Nature 395, 645-648[CrossRef][Medline] [Order article via Infotrieve]
59. Estacion, M., and Mordan, L. J. (1997) Cell. Signal. 9, 363-366[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
JCBHome page
C. V. Ly, C.-K. Yao, P. Verstreken, T. Ohyama, and H. J. Bellen
straightjacket is required for the synaptic stabilization of cacophony, a voltage-gated calcium channel {alpha}1 subunit
J. Cell Biol., April 3, 2008; 181(1): 157 - 170.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
J. Vela, M. I. Perez-Millan, D. Becu-Villalobos, and G. Diaz-Torga
Different kinases regulate activation of voltage-dependent calcium channels by depolarization in GH3 cells
Am J Physiol Cell Physiol, September 1, 2007; 293(3): C951 - C959.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
N. Gaborit, S. Le Bouter, V. Szuts, A. Varro, D. Escande, S. Nattel, and S. Demolombe
Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart
J. Physiol., July 15, 2007; 582(2): 675 - 693.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. Tuluc, G. Kern, G. J. Obermair, and B. E. Flucher
Computer modeling of siRNA knockdown effects indicates an essential role of the Ca2+ channel {alpha}2{delta}-1 subunit in cardiac excitation-contraction coupling
PNAS, June 26, 2007; 104(26): 11091 - 11096.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
J. Gazulla, I. Benavente, and M. Sarasa
New Therapies for Ataxia-Telangiectasia
Arch Neurol, April 1, 2007; 64(4): 607 - 608.
[Full Text] [PDF]


Home page
Endocr. Rev.Home page
S.-N. Yang and P.-O. Berggren
The Role of Voltage-Gated Calcium Channels in Pancreatic {beta}-Cell Physiology and Pathophysiology
Endocr. Rev., October 1, 2006; 27(6): 621 - 676.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S.-N. Yang and P.-O. Berggren
{beta}-Cell CaV channel regulation in physiology and pathophysiology
Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E16 - E28.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
C. Marionneau, B. Couette, J. Liu, H. Li, M. E. Mangoni, J. Nargeot, M. Lei, D. Escande, and S. Demolombe
Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart
J. Physiol., January 1, 2005; 562(1): 223 - 234.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. V. Ivanov, J. M. Ward, L. Tessarollo, D. McAreavey, V. Sachdev, L. Fananapazir, M. K. Banks, N. Morris, D. Djurickovic, D. E. Devor-Henneman, et al.
Cerebellar Ataxia, Seizures, Premature Death, and Cardiac Abnormalities in Mice with Targeted Disruption of the Cacna2d2 Gene
Am. J. Pathol., September 1, 2004; 165(3): 1007 - 1018.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. J. Dubel, C. Altier, S. Chaumont, P. Lory, E. Bourinet, and J. Nargeot
Plasma Membrane Expression of T-type Calcium Channel {alpha}1 Subunits Is Modulated by High Voltage-activated Auxiliary Subunits
J. Biol. Chem., July 9, 2004; 279(28): 29263 - 29269.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
T. Yasuda, R. J. Lewis, and D. J. Adams
Overexpressed Cav{beta}3 Inhibits N-type (Cav2.2) Calcium Channel Currents through a Hyperpolarizing Shift of "Ultra-slow" and "Closed-state" Inactivation
J. Gen. Physiol., March 29, 2004; 123(4): 401 - 416.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Tada, M. Ohmori, and H. Iida
Molecular Dissection of the Hydrophobic Segments H3 and H4 of the Yeast Ca2+ Channel Component Mid1
J. Biol. Chem., March 7, 2003; 278(11): 9647 - 9654.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
E. Perez-Reyes
Molecular Physiology of Low-Voltage-Activated T-type Calcium Channels
Physiol Rev, January 1, 2003; 83(1): 117 - 161.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
N. Qin, S. Yagel, M.-L. Momplaisir, E. E. Codd, and M. R. D'Andrea
Molecular Cloning and Characterization of the Human Voltage-Gated Calcium Channel alpha 2delta -4 Subunit
Mol. Pharmacol., September 1, 2002; 62(3): 485 - 496.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Tomizawa, T. Kohno, H. Kondo, A. Otsuka, M. Nishioka, T. Niki, T. Yamada, A. Maeshima, K. Yoshimura, R. Saito, et al.
Clinicopathological Significance of Epigenetic Inactivation of RASSF1A at 3p21.3 in Stage I Lung Adenocarcinoma
Clin. Cancer Res., July 1, 2002; 8(7): 2362 - 2368.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. Barclay, N. Balaguero, M. Mione, S. L. Ackerman, V. A. Letts, J. Brodbeck, C. Canti, A. Meir, K. M. Page, K. Kusumi, et al.
Ducky Mouse Phenotype of Epilepsy and Ataxia Is Associated with Mutations in the Cacna2d2 Gene and Decreased Calcium Channel Current in Cerebellar Purkinje Cells
J. Neurosci., August 15, 2001; 21(16): 6095 - 6104.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
D. G. Burbee, E. Forgacs, S. Zochbauer-Muller, L. Shivakumar, K. Fong, B. Gao, D. Randle, M. Kondo, A. Virmani, S. Bader, et al.
Epigenetic Inactivation of RASSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression
J Natl Cancer Inst, May 2, 2001; 93(9): 691 - 699.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
E. Marais, N. Klugbauer, and F. Hofmann
Calcium Channel alpha 2delta Subunits---Structure and Gabapentin Binding
Mol. Pharmacol., April 16, 2001; 59(5): 1243 - 1248.
[Abstract] [Full Text]


Home page
Arch NeurolHome page
J. Jen and D. H. Geschwind
Ataxia and Calcium Channels: What a Headache!
Arch Neurol, February 1, 2001; 58(2): 179 - 180.
[Full Text] [PDF]


Home page
Cancer Res.Home page
M. I. Lerman and J. D. Minna
The 630-kb Lung Cancer Homozygous Deletion Region on Human Chromosome 3p21.3: Identification and Evaluation of the Resident Candidate Tumor Suppressor Genes
Cancer Res., November 1, 2000; 60(21): 6116 - 6133.
[Abstract] [Full Text]


Home page
J. Physiol.Home page
S. Hering, S. Berjukow, S. Sokolov, R. Marksteiner, R. G Weiss, R. Kraus, and E. N Timin
Molecular determinants of inactivation in voltage-gated Ca2+ channels
J. Physiol., October 15, 2000; 528(2): 237 - 249.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
R. Felix
Channelopathies: ion channel defects linked to heritable clinical disorders
J. Med. Genet., October 1, 2000; 37(10): 729 - 740.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gao, B.
Right arrow Articles by Minna, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gao, B.
Right arrow Articles by Minna, J. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement